Limits...
Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies.

Pant N, Marcotte H, Brüssow H, Svensson L, Hammarström L - BMC Microbiol. (2007)

Bottom Line: The combination treatment reduced the diarrhea outcome measures significantly, prevented histopathological changes and reduced the virus load in the intestines.The advantages associated with immunoglobulins and probiotics based therapy is that the treatment provides a rapid therapeutic effect and is cost efficient.These components do not require special storage conditions and could potentially complement the rehydration therapy that is currently used.

View Article: PubMed Central - HTML - PubMed

Affiliation: Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden. neha.pant@ki.se

ABSTRACT

Background: Rotavirus is a worldwide cause of infectious infantile diarrhea that claims over 600,000 lives annually. Recently, two new vaccine candidates have been developed but their efficacy in developing countries, still remains to be proven. Oral delivery of specific immunoglobulins provides passive immunity and is a fast acting treatment for rotavirus diarrhea. Probiotic bacteria have also gained considerable attention lately as treatment for rotavirus diarrhea. Here we report an evaluation of the therapeutic potential of different probiotics and their combination with anti - rotavirus antibodies in a mouse model of rotavirus diarrhea.

Results: Of the six probiotic bacteria tested, Lactobacillus rhamnosus strain GG had the strongest influence in reducing prevalence, duration and severity of diarrhea and was therefore chosen for combination treatment with immunoglobulins. The combination treatment reduced the diarrhea outcome measures significantly, prevented histopathological changes and reduced the virus load in the intestines.

Conclusion: The advantages associated with immunoglobulins and probiotics based therapy is that the treatment provides a rapid therapeutic effect and is cost efficient. These components do not require special storage conditions and could potentially complement the rehydration therapy that is currently used.

Show MeSH

Related in: MedlinePlus

Reactivity of Hyperimmune bovine colostrums (HBC) against RRV. HBC preparation is highly reactive against RRV as assessed by ELISA. ELISA plates were coated with RRV and HBC was added in different dilutions. The reaction was developed using anti-bovine AP conjugated secondary antibody. Control colostrums preparation (Imulin®) does not show any cross-reactivity with RRV even at high concentrations.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2194776&req=5

Figure 1: Reactivity of Hyperimmune bovine colostrums (HBC) against RRV. HBC preparation is highly reactive against RRV as assessed by ELISA. ELISA plates were coated with RRV and HBC was added in different dilutions. The reaction was developed using anti-bovine AP conjugated secondary antibody. Control colostrums preparation (Imulin®) does not show any cross-reactivity with RRV even at high concentrations.

Mentions: HBC (Hyperimmune Bovine Colostrum) antibodies were highly reactive against RRV (Rhesus rotavirus) in ELISA, even at low concentrations (15 ng of total protein, corresponding to 5.4 ng of total immunoglobulins). A control colostrum preparation Imulin®, did not show any reactivity against RRV (Figure 1).


Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies.

Pant N, Marcotte H, Brüssow H, Svensson L, Hammarström L - BMC Microbiol. (2007)

Reactivity of Hyperimmune bovine colostrums (HBC) against RRV. HBC preparation is highly reactive against RRV as assessed by ELISA. ELISA plates were coated with RRV and HBC was added in different dilutions. The reaction was developed using anti-bovine AP conjugated secondary antibody. Control colostrums preparation (Imulin®) does not show any cross-reactivity with RRV even at high concentrations.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2194776&req=5

Figure 1: Reactivity of Hyperimmune bovine colostrums (HBC) against RRV. HBC preparation is highly reactive against RRV as assessed by ELISA. ELISA plates were coated with RRV and HBC was added in different dilutions. The reaction was developed using anti-bovine AP conjugated secondary antibody. Control colostrums preparation (Imulin®) does not show any cross-reactivity with RRV even at high concentrations.
Mentions: HBC (Hyperimmune Bovine Colostrum) antibodies were highly reactive against RRV (Rhesus rotavirus) in ELISA, even at low concentrations (15 ng of total protein, corresponding to 5.4 ng of total immunoglobulins). A control colostrum preparation Imulin®, did not show any reactivity against RRV (Figure 1).

Bottom Line: The combination treatment reduced the diarrhea outcome measures significantly, prevented histopathological changes and reduced the virus load in the intestines.The advantages associated with immunoglobulins and probiotics based therapy is that the treatment provides a rapid therapeutic effect and is cost efficient.These components do not require special storage conditions and could potentially complement the rehydration therapy that is currently used.

View Article: PubMed Central - HTML - PubMed

Affiliation: Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden. neha.pant@ki.se

ABSTRACT

Background: Rotavirus is a worldwide cause of infectious infantile diarrhea that claims over 600,000 lives annually. Recently, two new vaccine candidates have been developed but their efficacy in developing countries, still remains to be proven. Oral delivery of specific immunoglobulins provides passive immunity and is a fast acting treatment for rotavirus diarrhea. Probiotic bacteria have also gained considerable attention lately as treatment for rotavirus diarrhea. Here we report an evaluation of the therapeutic potential of different probiotics and their combination with anti - rotavirus antibodies in a mouse model of rotavirus diarrhea.

Results: Of the six probiotic bacteria tested, Lactobacillus rhamnosus strain GG had the strongest influence in reducing prevalence, duration and severity of diarrhea and was therefore chosen for combination treatment with immunoglobulins. The combination treatment reduced the diarrhea outcome measures significantly, prevented histopathological changes and reduced the virus load in the intestines.

Conclusion: The advantages associated with immunoglobulins and probiotics based therapy is that the treatment provides a rapid therapeutic effect and is cost efficient. These components do not require special storage conditions and could potentially complement the rehydration therapy that is currently used.

Show MeSH
Related in: MedlinePlus